Ranibizumab Versus Aflibercept for Macular Edema Secondary to Non-ischemic Central Retinal Vein Occlusion in Young Adult Patients.
Overview
- Phase
- Phase 4
- Intervention
- Aflibercept
- Conditions
- Non-Ischemic Central Retinal Vein Occlusion With Macular Edema
- Sponsor
- South Valley University
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Best corrected visual acuity BCVA
- Last Updated
- 4 years ago
Overview
Brief Summary
this study will compare the efficacy and safety of use either Ranibizumab and Aflibercept in treatment of macular edema resulting from non ischemic central retinal vein occlusion in patients younger than 5o years old
Detailed Description
This is a prospective randomized interventional study, Forty eyes of forty patients younger than 50 years with macular edema due to non-ischemic CRVO were enrolled in the study. Patients will be randomized into 2 groups. First group will receive intravitreal injection of Ranibizumab 0.5 mg\\0.1ml. the second group will receive intravitreal injection of 2.0 mg\\0.1 ml Aflibercept. All patients will be followed up for 12 months.
Investigators
Ahmed Ali Ahmed Amer
Ophthalmology department Qena Faculty of medicine, South Valley University, Egypt
South Valley University
Eligibility Criteria
Inclusion Criteria
- •patients younger than 50 years with macular edema due to non-ischemic CRVO
Exclusion Criteria
- •Other conditions that might affect the macula as
- •diabetic retinopathy, intraocular inflammation, age related macular degeneration, patients with solar or radiation retinopathy,
- •patients with ischemic type CRVO and patients who had recent intraocular surgery.
- •patients who had previous intravitreal injections, ophthalmic laser surgeries.
- •patients with dense cataracts whom fundus was difficult to scan.
- •Patients who were lost to follow up visits were also excluded
Arms & Interventions
Aflibercept group
Aflibercept injection monthly for 3 successive months
Intervention: Aflibercept
Ranibizumab group
Ranibizumab injection monthly for 3 successive months
Intervention: intravitreal injection of Ranibizumab
Ranibizumab group
Ranibizumab injection monthly for 3 successive months
Intervention: Ranibizumab
Aflibercept group
Aflibercept injection monthly for 3 successive months
Intervention: intravitreal injection of Aflipercept
Outcomes
Primary Outcomes
Best corrected visual acuity BCVA
Time Frame: at 12 months post-injection
change BCVA after injection
Secondary Outcomes
- reduction of macular edema(at 12 months post-injection)